Basilea owns a broad and balanced late-stage product portfolio including novel treatments for resistant bacterial infections, systemic fungal infections and severe skin diseases. The company's diversified portfolio includes two commercialized drugs (alitretinoin, ceftobiprole), one investigational drug in phase III (isavuconazole) as well as innovative earlier-stage programs. Basilea has entered into a license, co-development and co-promotion agreement with Astellas Pharma Inc. for isavuconazole for the treatment of life-threatening invasive fungal infections on a worldwide basis, including an option for Japan. Toctino® (alitretinoin) is marketed in Denmark, France, Germany, Switzerland and the United Kingdom. It is approved in six additional European countries as well as in Canada and has been recommended for approval in 15 European countries. Furthermore, a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ and in Switzerland under Zevtera™.

Basilea has a fully integrated R&D organization and has set up commercial organizations in Canada, France, Germany, the Nordics, Switzerland and the United Kingdom, while it is building sales and marketing organizations in other countries to commercialize alitretinoin, subject to approval.